Split-Protein CAR Systems for Targeted Cancer Immunotherapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cancer treatments using chimeric antigen receptors (CARs) lack specificity and control over targeting, particularly for tumors with inappropriate expression of chondroitin sulfate A (CSA) modifications, and existing CARs are not easily pharmacologically controlled.
Innovation Solution
Development of VAR2CSA-fused CARs and split-protein binding systems, such as Spy-CAR, which utilize high-affinity binding between VAR2CSA and CSA to target cancer cells, allowing for precise immune response activation and deactivation, and the use of recombinant T-cells expressing these CARs for immunotherapy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional CARs are used for cancer treatment, then immune cells can be modified to express synthetic proteins for tumor targeting, but the treatments lack specificity and control over targeting
Solution Approach 1:
The patent divides the CAR system into separate components: a CAR expression vector and a separate antigen-binding protein (such as scFv or antibody). The CAR on immune cells provides one function (immune activation), while the separate antigen-binding protein provides another function (target recognition). This segmentation allows independent optimization and control of each component, improving targeting specificity while maintaining ease of operation.
Solution Approach 2:
The patent introduces an intermediary antigen-binding protein that acts as a mediator between the CAR-expressing immune cell and the tumor target. This intermediary protein can be designed with high specificity for tumor antigens, thereby improving targeting specificity. The separate nature of this intermediary also allows for better control over when and where the immune response is activated.
2Adaptability or versatility
If existing CARs are used, then cancer cells can be targeted, but the CARs are not easily pharmacologically controlled
Solution Approach 1:
The patent creates a dynamic CAR system where the antigen-binding capability can be modulated independently from the immune activation function. The separate antigen-binding protein can be designed to respond to pharmacological agents, allowing dynamic control of target recognition. This enables the system to adapt to different treatment requirements without increasing overall complexity.
Solution Approach 2:
The patent designs a universal CAR platform that can work with multiple different antigen-binding proteins. The core CAR structure remains the same, but different antigen-binding proteins can be swapped in to target different tumor types or respond to different pharmacological controls. This universality provides pharmacological adaptability without requiring complex redesign of the entire CAR system for each application.
3Measurement precision
If high-affinity binding between VAR2CSA and CSA is utilized, then precise immune response activation is achieved, but the system complexity increases
Solution Approach 1:
The patent extracts the high-affinity binding function from the CAR construct itself and places it in a separate antigen-binding protein (such as a scFv or antibody that binds CSA). This extraction maintains the precision of immune response activation while reducing the complexity of the CAR construct. The CAR becomes simpler, focusing only on immune cell engagement and activation, while the separate protein handles the high-specificity target recognition.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The VAR2CSA-fused CARs and split-protein binding systems enable targeted immune responses against cancer cells with CSA modifications, offering precise and controlled treatment options, including the ability to change targeting molecules during treatment, thereby improving treatment efficacy and minimizing adverse effects.
Implementation Method 1
The SpyTag and SpyCatcher interact via a spontaneous isopeptide bond formation
Implementation Method 2
recombinant full-length VAR2CSA ecto-domain from FCR3 and 3D7 type parasites has shown affinity for CSA in the low nano-molar range
Data Source
AI summary
The present invention relates to polypeptides comprising conditionally active chimeric antigen receptor (CAR) and a split-protein binding system, a VAR2CSA polypeptide, or any other targeting agent. The present invention further relates to polypeptides comprising VAR2CSA polypeptides or other targeting agent, and a split-protein binding system.